LONGMONT, CO--(Marketwired - Apr 29, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that the Company has begun its planned California expansion strategy.
Since Assembly Bill 2312 was passed in 2012, the medical marijuana industry has thrived in the State of California. With only medical marijuana currently legal, the California market is ripe for MediJane to launch its first product in the state. To realize this goal, regulatory applications and filings are in place and steps are being taken to ensure that MediJane products will be compliant with all California laws.
"State by state product regulatory compliance is going to be an on-going factor for any growing medical marijuana focused company," commented Ronald Lusk, CEO of MediJane Holdings Inc. "Another major factor to our long-term success will be our ability to build and maintain a motivated, capable, and experienced sales force across the country."
Mr. Lusk concluded, "Now that we have our State of California regulatory applications and filings in place, we have started the search for our new California sales manager. Because MediJane is a medical marijuana company with innovative proprietary medical delivery systems, the California sales manager position will require a delicate balance of science and sales, and will also need to have a diverse understanding of the medical and recommending doctors industries. We are confident that our current efforts to fill this important position will be successful and that MediJane products will be well received in California."
The Company anticipates that the innovative MediJane "Daytime plus CBD" pain and inflammation management product could be on store shelves in California within the next 60 days, subject to final regulatory approvals. "Daytime plus CBD" targets chronic, neuropathic, arthritic, and back pain, without drowsiness. The four (4) hour dosage allows for accurate and controlled delivery of cannabinoids directly into the pain sufferer's system. This smokeless alternative is MediJane's initial launch into the chronic pain management market, which is estimated at over $45 billion annually in North America.
About MediJane Holdings Inc. (MJMD)
MediJane Holdings Inc. (MJMD) is in the business of marketing and distributing products within the medical marijuana industry, including transdermal patches, capsules, sublingual sprays, and other medical delivery systems. With sales offices opening in California and Colorado, and a planned expansion into a national footprint, MediJane products are designed to give doctors the ability to provide patients accurate and effective doses of cannabinoids to manage and treat pain and other specific illnesses. MediJane's lead product is an innovative non-drowsy "Daytime Pain plus CBD" oral capsule for the treatment of inflammation and chronic, neuropathic, arthritic, and back pain. This smokeless and accurate dose alternative is MediJane's initial launch into the chronic pain management market, which is estimated at over $45 billion annually in North America.
For more information, visit www.medijane.co
Disclaimer/Safe Harbor: Some information in this MediJane Holdings Inc. (MJMD) press release constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause MJMD's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to MJMD herein are expressly qualified in their entirety by the above-mentioned cautionary statement. MJMD disclaims any obligation to update forward-looking statements contained in this press release, except as may be required by law.